{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:43:32Z","timestamp":1791895412666,"version":"4.3.4"},"reference-count":8,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,16]]},"abstract":"<jats:p>In this month\u2019s CME article, Vercellino and colleagues report results of a secondary analysis of diffuse large B-cell lymphoma patients in the REMARC trial who had baseline positron emission tomography scans, thereby demonstrating that metabolic tumor volume combined with performance status allowed risk stratification of patients before treatment and predicted survival independent of response to chemoimmunotherapy.<\/jats:p>","DOI":"10.1182\/blood.2020005002","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T19:14:44Z","timestamp":1587064484000},"page":"1308-1309","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Predicting the future for DLBCL"],"prefix":"10.1182","volume":"135","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[{"name":"Lymphoma Research Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2020041612081285100_B1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"key":"2020041612081285100_B2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"Development of a predictive model for aggressive lymphoma: The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"2020041612081285100_B3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","article-title":"Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"13","key":"2020041612081285100_B4","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2020041612081285100_B5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"15","key":"2020041612081285100_B6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020041612081285100_B7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(5):1292; Nat Med. 2018;24(5): 1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2020041612081285100_B8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/16\/1308\/1724155\/bloodbld2020005002c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/16\/1308\/1724155\/bloodbld2020005002c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T19:14:47Z","timestamp":1587064487000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/16\/1308\/454347\/Predicting-the-future-for-DLBCL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":8,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,4,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005002","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}